Health Catalyst (HCAT) Net Income towards Common Stockholders (2018 - 2026)

Health Catalyst has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$111.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 367.64% year-over-year to -$111.0 million; the trailing twelve-month figure through Mar 2026 stood at -$265.3 million (down 265.08% YoY), and the FY2025 full-year result was -$178.0 million, down 156.07% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$111.0 million, down from -$91.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$13.5 million in Q2 2024, with the low at -$111.0 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$36.1 million across 5 years, with a median of -$30.3 million in 2023.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 58.56% — and 2026, when it tumbled 367.64%.
• Health Catalyst's Net Income towards Common Stockholders stood at -$35.7 million in 2022, then climbed by 15.19% to -$30.3 million in 2023, then jumped by 31.8% to -$20.7 million in 2024, then plunged by 340.31% to -$91.0 million in 2025, then slipped by 21.97% to -$111.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$111.0 million (Q1 2026), -$91.0 million (Q4 2025), and -$22.2 million (Q3 2025), per Business Quant data.